Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Journal of Hematology & Oncology|December 15, 2023
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2Sara Pusceddu, Francesca Corti, Natalie Prinzi, et al.
Cancer Medicine|May 27, 2017
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumorsRossana Berardi, Mariangela Torniai, Sara Pusceddu, et al.
Cancer Medicine|December 2, 2024
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic CancerFederico Nichetti, Marco Silvestri, Luca Agnelli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomasAlberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Virchows Archiv : an International Journal of Pathology|January 3, 2024
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectivesMichele Simbolo, Giovanni Centonze, Anastasios Gkountakos, et al.
Journal of Neuroendocrinology|November 19, 2025
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and managementNicola Fazio, Patrick Maisonneuve, Anna Maria Frezza, et al.
The Oncologist|August 14, 2014
Real-world study of everolimus in advanced progressive neuroendocrine tumorsFrancesco Panzuto, Maria Rinzivillo, Nicola Fazio, et al.
Cancers|October 14, 2022
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic ImplicationsMichele Simbolo, Giovanni Centonze, Luca Giudice, et al.
Molecular Oncology|May 27, 2022
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancersMonica Niger, Federico Nichetti, Andrea Casadei-Gardini, et al.
Journal of Neuroendocrinology|June 22, 2023
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECISTLouis de Mestier, Matthieu Resche-Rigon, Clarisse Dromain, et al.
Pageof 12